Chris Parker
@pcaparker
Prostate oncologist, cyclist, would-be climate activist
ID: 4858558163
28-01-2016 21:14:25
2,2K Tweet
2,2K Followers
870 Following
Why is climate change a health crisis? Find out more about your specialties and what you can do to tackle climate change TOMORROW, 17th September. #WorldPatientSafetyDay2024 #OurHealthOurPlanet Join the launch: eventbrite.co.uk/e/our-health-o… Centre for Sustainable Healthcare UK Health Alliance on Climate Change
Presented at #ESMO24 and published simultaneously The Lancet Oncology: thelancet.com/journals/lanon… The randomised ph2 UpFrontPSMA study: Sequential [177Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive #prostatecancer
During earlier debates on euthanasia, Dominic Lawson & George Pitcher brilliantly argued for “care not kill.”Movingly,Alison Davis said she had been given 25 years of extra life which would have been denied if her wish to die had been granted:missing “the best years of my life.”
Check out this great discussion between Oliver Sartor and Alicia Morgans, MD, MPH > bit.ly/47ojcyV, written coverage from #ESMO24 > bit.ly/3Xqx3A3
#ProstateCancer efficacy results from a randomized phase 3 evaluation of transdermal estradiol vs LHRH agonists for androgen suppression in M0 prostate cancer. Presented by Ruth Langley, PhD MRC Clinical Trials Unit at UCL. #ESMO24 written coverage by Zach Klaassen > bit.ly/4d6XNLN
Third #Stampede presentation by silke gillessen. Metformin has weak effect on OS with possible interaction with disease volume. Significant positive effects on metabolic outcomes MRC Clinical Trials Unit at UCL The ICR
Second #Stampede presentation today silke gillessen on metformin in M1HSPC. Borderline OS gain, ?more in HV disease. Significant metabolic gains all pts MRC Clinical Trials Unit at UCL The ICR
Neeraj Agarwal, MD, FASCO silke gillessen ESMO - Eur. Oncology UroToday.com PCF Science OncoAlert Cancer Research UK Sumanta K. Pal, MD, FASCO Tian Zhang, MD, MHS Petros Grivas Shilpa Gupta Yüksel Ürün Umang Swami GU Cancer Research Program @HuntsmanCancer Bogdana Schmidt MD, MPH Arun Azad Ravindran Kanesvaran But there were favorable metabolic effects, which could be impactful in overall health and longevity
Sequential [177Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA) out on The Lancet Oncology and presented at #ESMO24 thelancet.com/journals/lanon… The UpFrontPSMA phase 2 trial evaluated the use of Lutetium-177